Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 Gain-of-Function Mutation is a Poor Prognostic Factor in High-Methylated Metastatic Colorectal Cancer.

Clinical colorectal cancer - 1 Sept 2023

Wakayama Shonosuke, Ouchi Kota, Takahashi Shin, Yamada Yasuhide, Komatsu Yoshito, Shimada Ken, Yamaguchi Tatsuro, Shirota Hidekazu, Takahashi Masanobu, Ishioka Chikashi

Abstract excerpt

BACKGROUND: Neither TP53 mutation nor DNA methylation status has been established as a biomarker alone of metastatic colorectal cancer. We analyzed the association between TP53 mutation functional subtypes and genome-wide DNA methylation status (GWMS) as combined prognostic markers. METHODS: Patient clinical data were obtained from the TRICOLORE study, a randomized phase III trial. The TP53 mutations were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Colorectal Cancer Treatments and Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Epigenetics and DNA Methylation

Share to Mutation

Share to Prognosis

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 37355363
DOI: 10.1016/j.clcc.2023.06.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 Gain-of-Function Mutation is a Poor Prognostic Factor in High-Methylated Metastatic Colorectal Cancer.PMID 37355363Read ↗

The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations.Semantic proximity Read ↗

Clinical impact of TP53 mutation status on survival outcomes in metastatic colorectal cancer.Semantic proximity Read ↗

RAS/BRAF wild-type metastatic high-methylated colorectal cancer has gene expression patterns related to MSI-H and BRAF V600E mutant: a translational research.Semantic proximity Read ↗

Clinical significance of TP53 mutations in patients with acute myeloid leukemia: the HM-SCREEN-JAPAN 01/02 study.Semantic proximity Read ↗

Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors.Semantic proximity Read ↗

Genome-wide DNA methylation analysis reveals a prognostic classifier for non-metastatic colorectal cancer (ProMCol classifier)Semantic proximity Read ↗

The prognostic role of p53 mutations in metastatic colorectal cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

Effect of DNA methylation status on first-line anti-epidermal growth factor receptor treatment in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Can TP53, TMB and TME Expand the Immunotherapy Benefit in Metastatic Colorectal Cancer?Semantic proximity Read ↗

DNA methylation status as a biomarker of anti‐epidermal growth factor receptor treatment for metastatic colorectal cancerSemantic proximity Read ↗

Gain-of-function miRNA signature by mutant p53 associates with poor cancer outcomeSemantic proximity Read ↗

Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.